Using mesenchymal stem cells for blood purification to treat liver failure

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the safety and effectiveness of mesenchymal stem cells used in blood purification for treating liver failure in adults. Participants will receive standard medical treatment alongside blood purification that utilizes these stem cells, which operate outside the body. The study will collect various biological samples and monitor outcomes such as survival rates and liver disease indicators over several weeks. The primary focus is to determine if this innovative approach can improve patient conditions and identify any associated medical issues.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age range from 18 to 65 years old;
2. Patients with acute liver failure in the early and intermediate stages caused by various reasons;
3. Total bilirubin (TBil) ≥ 171μmol/L or an increase of ≥ 17.1μmol/L per day;
4. Prothrombin activity (PTA) between 20% and 40% (or INR between 1.5 and 2.6);
5. No hepatic encephalopathy or encephalopathy below grade II (including grade II);
6. Elevated inflammatory markers (IL-6 / TNF-α / CRP, etc.);
7. The subjects are able to communicate well with the researchers and can complete the study in accordance with the study regulations;
8. The subjects must be informed of this study and voluntarily sign a written informed consent form before the experiment.

Exclusion Criteria:

1. Patients with severe active bleeding or diffuse intravascular coagulation;
2. Patients with a high degree of allergy to blood products or drugs used during treatment, such as plasma, heparin, and protamine;
3. Patients with circulatory failure;
4. Patients with a MELD score \> 30;
5. Patients with other severe heart diseases, lung diseases, blood diseases, autoimmune diseases, or diabetes;
6. Subjects who may be unable to complete this study for other reasons or who the researchers believe should not be included.

Where it's running

• Zhujiang hospital
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: Kebo Zhong, doctor
• Email: zhongkb@smu.edu.cn
• Phone: 8615360629197

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Predicting liver failure after major liver surgery using CT measurements and vascular shape changes

  Doctors are testing whether adding vascular deformation mapping to CT measurements can better predict liver failure after removing a large portion of the liver.

  Recruiting at 3 sites Minia University · Minya, Minya Governorate and 2 other locations · NCT07727759

• Liver transplant with TLI and ATG conditioning to try stopping or reducing immunosuppression

  This trial tests whether a conditioning regimen with Total Lymphoid Irradiation and Anti-Tthymocyte Globulin after a liver transplant can help patients stop or minimize their immunosuppressive drugs over time.

  Recruiting Phase 1/2 Stanford University · Stanford, California · NCT07634562

• New bioartificial liver for people with liver failure or small-for-size syndrome

  This trial will test a bioartificial liver using hepatocytes made from chemically induced pluripotent stem cells to see if it is safe and tolerated in people with liver failure or small-for-size syndrome.

  Recruiting Phase 1/2 Beijing Friendship Hospital · Beijing · NCT07312864

• CRISPR-edited donor liver transplant to reduce rejection

  This trial will try transplanting deceased-donor livers that have had key HLA genes removed with CRISPR to see if they cause less rejection in adults needing a liver transplant.

  Recruiting Phase 1/2 American Organ Transplant and Cancer Research Institute LLC · Beijing, Changping · NCT07053488

• Evaluating citrate anticoagulation in kidney treatment for liver failure patients

  This study is testing if using citrate anticoagulation during kidney treatment helps critically ill patients with liver failure and kidney injury recover better and live longer.

  Recruiting University Hospital, Antwerp · Edegem, Antwerp · NCT06908746

• Microbiota augmentation to restore healthy gut bacteria in hospitalized liver patients

  This trial will test whether giving defined groups of healthy gut bacteria is safe and can restore key gut metabolites in hospitalized adults with liver disease who have low fecal butyrate and deoxycholic acid.

  Recruiting Phase 1 University of Chicago · Chicago, Illinois · NCT06871111

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.